医学通信公司
期刊
会议
图书
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1559)医学通信公司
摘要:The FDA has approved the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (Calquence – AstraZeneca) for oral treatment of relapsed or refractory mantle cell lymphoma. Acalabrutinib is the second BTK inhibitor to be approved for this indication; ibrutinib (Imbruvica) was ...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1559)医学通信公司
摘要:The FDA has approved cannabidiol oral solution (Epidiolex – Greenwich Biosciences) for treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in patients ≥2 years old. Cannabidiol (CBD) is a cannabinoid constituent of the marijuana plant (Cannabis s...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1559)医学通信公司
摘要:The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm (Ajovy – Teva) and galcanezumab-gnlm (Emgality – Lilly), for migraine prevention in adults. Fremanezumab and galcanezumab are the second and third subcutane...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1559)医学通信公司
摘要:The FDA has approved the new aminoglycoside antibiotic plazomicin (Zemdri – Achaogen) for IV treatment of adults with complicated urinary tract infections (cUTIs). Plazomicin is active against multi-drug- resistant Enterobacteriaceae, including strains resistant to other ami...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1559)医学通信公司
摘要:The FDA has approved the anti-CD30 antibody-drug conjugate brentuximab vedotin (Adcetris – Seattle Genetics) for use in combination with chemotherapy for IV treatment of adults with previously untreated stage 3 or 4 classical Hodgkin's lymphoma (cHL). Adcetris was approved e...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1558)医学通信公司
摘要:The FDA has approved an over-the-counter (OTC) 0.025% ophthalmic formulation of the selective alpha2-adrenergic agonist brimonidine tartrate (Lumify – Bausch & Lomb) for treatment of ocular redness in adults and children ≥5 years old. Lumify is the first brimonidine product ...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1558)医学通信公司
摘要:Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old. Recommendations for the current season for specific patient populations are listed in Tables 2 and 4.
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1558)医学通信公司
摘要:The FDA has approved the fixed-dose combination of tezacaftor and ivacaftor (Symdeko – Vertex) for oral treatment of cystic fibrosis (CF) in patients ≥12 years old who are homozygous for the F508del (also called Phe508del or ΔF508) mutation or have at least one mutation...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1557)医学通信公司
摘要:Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also highly effective in preventing pregnancy. When used alone, barrier and fertility-base...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1556)医学通信公司
摘要:The FDA has approved hydrogen peroxide 40% topical solution (Eskata – Aclaris Therapeutics) for treatment of raised seborrheic keratoses (SKs) in adults. It is the first drug to be approved for this indication. (Hydrogen peroxide is available over the counter for topical use...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×